Northern Trust enters the back half of July with an unusual tension: the stock is slightly down on the week even as options traders have moved to their most bullish posture in months, and a broad wave of analyst target upgrades has yet to fully lift the share price above $185.
Options positioning is the sharpest signal this week. The put/call ratio has collapsed to 0.36 — more than two standard deviations below its 20-day average of 0.53 and the lowest reading since the 52-week floor of 0.037. That means call demand is overwhelming put buying by a margin not seen in at least a year, a posture more consistent with investors chasing upside than hedging downside. The move is particularly striking given that NTRS itself closed Tuesday at $185.06, up just 1.2% on the day but still off roughly 0.8% on the week. Call buyers are leaning into a narrative the price action hasn't yet confirmed.
The lending market offers no conflicting signal — shorts are simply not a factor here. Short interest is running at just 1.7% of the free float, and while that figure has climbed roughly 27% over the past month in share terms, the absolute level remains low. Borrow is near-free at 0.41% annualised, and availability is essentially unlimited, with shares available to lend dwarfing current short demand by a factor of more than 100. The short score of 32 is unremarkable. There is no squeeze dynamic, no crowded short thesis, no meaningful cost-of-borrow pressure — the borrow market is a non-event.
The Street has been busy revising upward, though the direction of travel masks a persistent ratings overhang. Almost every major firm raised its target in late June and early July: BofA lifted to $200 (the only outright Buy in the sample), JPMorgan moved to $179.50, Wells Fargo to $189, and Truist to $186. Keefe Bruyette moved its target to $175 — while keeping an Underperform — and Morgan Stanley bumped to $170 while holding Underweight. The mean target across the group sits at $179.73, actually a touch below Tuesday's close of $185.06, which means the stock has already traded through consensus. That mismatch underscores the tension: targets have been rising, but the stock has outrun them, and the majority of named analysts remain neutral-to-negative on the rating. The bull case hinges on continued improvement in noninterest income and operating leverage flagged in Q2; the bear case centres on loan book softness, funding cost drag, and macro uncertainty around trade policy. Factor scores are constructive — EPS momentum ranks in the 85th percentile on a 30-day basis, and dividend quality scores at the 88th percentile — but the analyst recommendation score sits only at the 46th percentile, reflecting how crowded the neutral/underperform camp remains despite the target inflation.
On the institutional side, the register is dominated by index-driven flows. BlackRock added around 265,000 shares as of end-June, State Street added 88,000, and Geode added 150,000 — all consistent with passive rebalancing rather than active conviction. Insider activity over the past 90 days nets to a modest positive in share terms, though that headline figure is dominated by a CFO sale of nearly 20,000 shares at $166 in late April, partially offset by smaller director purchases. Nothing in the insider log suggests unusual conviction in either direction at current levels.
The next formal catalyst is the Q3 earnings print scheduled for October 21. What to watch between now and then is whether the options market's extreme call skew fades as the post-Q2 enthusiasm digests, and whether any of the neutral-rated analysts — JPMorgan, Morgan Stanley, Citi — follow BofA's lead and step up to a positive rating now that targets across the group have been reset higher.
See the live data behind this article on ORTEX.
Open NTRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
